Boehringer Ingelheim: Head and Neck Neoplasms trials
The registry lists 13 Head and Neck Neoplasms studies with Boehringer Ingelheim as lead sponsor. 0 are open to participants now and 6 have results posted.
Phase 1 6Phase 2 1Phase 3 6(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091TerminatedNCT03780725Phase 1Results posted
- LUX-Head & Neck 4: Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapyTerminatedNCT02131155Phase 3Results posted
- LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based ChemotherapyCompletedNCT01856478Phase 3Results posted
- LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based ChemotherapyCompletedNCT01345682Phase 3Results posted
- LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapyTerminatedNCT01345669Phase 3Results posted
- BIBW 2992 (Afatinib) in Head & Neck CancerCompletedNCT00514943Phase 2Results posted
- A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6TerminatedNCT06091930Phase 1
- A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell SurfaceCompletedNCT04752215Phase 1
- Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and NeckCompletedNCT02254018Phase 1
- Pharmacokinetic Study of Porfiromycin in Head and Neck Cancer and Other Cancer Patients With Solid TumorsTerminatedNCT02209701Phase 1
- Dose Escalation Study With 99mTC - or 186 Re-labelled Humanised Monoclonal Antibody (hMAb) BIWA 4 in Patients With Head and Neck CancerCompletedNCT02204033Phase 1
- Porfiromycin Used as an Adjuvant to Radiation Therapy in Postoperative Head and Neck Cancer PatientsTerminatedNCT02183246Phase 3
- Radiation Therapy Plus Porfiromycin in Treating Patients With Stage III or Stage IV Head and Neck CancerCompletedNCT00003328Phase 3